IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer

Gynecologic Oncology

Volumn 145, Issue 3, 2017, Pages 453-461

  Felices, M ^a   Chu, S ^a   Kodal, B ^a   Bendzick, L ^b   Ryan, C ^b   Lenvik, A J ^a   Boylan, K L M ^a   Wong, H C ^c   Skubitz, A P N ^a,b   Miller, J S ^a   Geller, M A ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c ALTOR BIOSCIENCE CORPORATION   (United States)

Author keywords

IL 15 super agonist; Immunotherapy; Natural killer cells; Ovarian cancer

Indexed keywords

ALT 803; CYTOKINE RECEPTOR AGONIST; GAMMA INTERFERON; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ALT-803; INTERLEUKIN 15; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CELL FUNCTION; CELL PROLIFERATION; CHROMIUM RELEASE ASSAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUSE MODEL; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NOD SCID GAMMA MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; TARGET CELL; TUMOR XENOGRAFT; AGONISTS; ANIMAL; DRUG EFFECTS; DRUG SCREENING; FEMALE; IMMUNOLOGY; K-562 CELL LINE; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; NONOBESE DIABETIC MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; SCID MOUSE;

ANIMALS; ASCITES; FEMALE; HUMANS; INTERLEUKIN-15; K562 CELLS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; MICE, SCID; OVARIAN NEOPLASMS; PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85013456449     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2017.02.028     Document Type: Article

References (45)

1. Jemal, A., Siegel, R., Xu, J., Ward, E., Cancer statistics. CA Cancer J. Clin. 60:5 (2010), 277–300 (PubMed PMID: 20610543).
2. Kandalaft, L.E., Powell, D.J. Jr., Singh, N., Coukos, G., Immunotherapy for ovarian cancer: what's next?. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29:7 (2011), 925–933, 10.1200/JCO.2009.27.2369 Epub 2010/11/17. PubMed PMID: 21079136; PMCID: 3068064.
3. Galic, V., Coleman, R.L., Herzog, T.J., Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways. Curr. Cancer Drug Targets 13:6 (2013), 698–707 Epub 2013/05/17. PubMed PMID: 23675882.
4. Zhang, L.C.-G.J., Katsaros, D., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 (2003), 203–213.
5. Tomsova, M., Melichar, B., Sedlakova, I., Steiner, I., Prognostic significance of CD3 + tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol. Oncol. 108:2 (2008), 415–420, 10.1016/j.ygyno.2007.10.016 Epub 2007/11/27. PubMed PMID: 18037158.
6. Sato, E., Olson, S.H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A.A., Frosina, D., Gnjatic, S., Ambrosone, C., Kepner, J., Odunsi, T., Ritter, G., Lele, S., Chen, Y.T., Ohtani, H., Old, L.J., Odunsi, K., Intraepithelial CD8 + tumor-infiltrating lymphocytes and a high CD8 +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 102:51 (2005), 18538–18543, 10.1073/pnas.0509182102 Epub 2005/12/14. PubMed PMID: 16344461; PMCID: 1311741.
7. Carlsten, M., Bjorkstrom, N.K., Norell, H., Bryceson, Y., van Hall, T., Baumann, B.C., Hanson, M., Schedvins, K., Kiessling, R., Ljunggren, H.G., Malmberg, K.J., DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 67:3 (2007), 1317–1325 PubMed PMID: 17283169.
8. Geller, M.A., Knorr, D.A., Hermanson, D.A., Pribyl, L., Bendzick, L., McCullar, V., Miller, J.S., Kaufman, D.S., Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy 15:10 (2013), 1297–1306, 10.1016/j.jcyt.2013.05.022 PubMed PMID: 23993303; PMCID: PMC3775496.
9. Farag, S.S., Caligiuri, M.A., Human natural killer cell development and biology. Blood Rev. 20:3 (2006), 123–137, 10.1016/j.blre.2005.10.001 Epub 2005/12/21. PubMed PMID: 16364519.
10. Gammaitoni, L., Leuci, V., Mesiano, G., Giraudo, L., Todorovic, M., Carnevale-Schianca, F., Aglietta, M., Sangiolo, D., Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. Expert. Opin. Biol. Ther. 14:9 (2014), 1259–1270, 10.1517/14712598.2014.918099 Epub 2014/05/20. PubMed PMID: 24835841.
11. Patankar, M.S., Jing, Y., Morrison, J.C., Belisle, J.A., Lattanzio, F.A., Deng, Y., Wong, N.K., Morris, H.R., Dell, A., Clark, G.F., Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol. Oncol. 99:3 (2005), 704–713, 10.1016/j.ygyno.2005.07.030 Epub 2005/08/30. PubMed PMID: 16126266.
12. Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., Brossay, L., Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12:4 (2012), 239–252, 10.1038/nri3174 Epub 2012/03/23. PubMed PMID: 22437937.
13. Foley, B., Felices, M., Cichocki, F., Cooley, S., Verneris, M.R., Miller, J.S., The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol. Rev. 258:1 (2014), 45–63, 10.1111/imr.12157 Epub 2014/02/13. PubMed PMID: 24517425; PMCID: 3927144.
14. Stringaris, K., Sekine, T., Khoder, A., Alsuliman, A., Razzaghi, B., Sargeant, R., Pavlu, J., Brisley, G., de Lavallade, H., Sarvaria, A., Marin, D., Mielke, S., Apperley, J.F., Shpall, E.J., Barrett, A.J., Rezvani, K., Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica 99:5 (2014), 836–847, 10.3324/haematol.2013.087536 Epub 2014/02/04. PubMed PMID: 24488563; PMCID: 4008119.
15. Geller, M.A., Cooley, S., Judson, P.L., Ghebre, R., Carson, L.F., Argenta, P.A., Jonson, A.L., Panoskaltsis-Mortari, A., Curtsinger, J., McKenna, D., Dusenbery, K., Bliss, R., Downs, L.S., Miller, J.S., A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13:1 (2011), 98–107, 10.3109/14653249.2010.515582 Epub 2010/09/21. PubMed PMID: 20849361; PMCID: 3760671.
16. Lukesova, S., Vroblova, V., Tosner, J., Kopecky, J., Sedlakova, I., Cermakova, E., Vokurkova, D., Kopecky, O., Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma. Contemp. Oncol. (Pozn) 19:4 (2015), 290–299, 10.5114/wo.2015.54388 PubMed PMID: 26557777; PMCID: PMC4631306.
17. Belisle, J.A., Gubbels, J.A., Raphael, C.A., Migneault, M., Rancourt, C., Connor, J.P., Patankar, M.S., Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 122:3 (2007), 418–429, 10.1111/j.1365-2567.2007.02660.x PubMed PMID: 17617155; PMCID: PMC2266014.
18. Fumita, Y., Tanaka, F., Saji, F., Nakamuro, K., Immunosuppressive factors in ascites fluids from ovarian cancer patients. Am. J. Reprod. Immunol. 6:4 (1984), 175–178 PubMed PMID: 6528882.
19. Onsrud, M., Immunosuppressive effects of peritoneal fluids from ovarian cancer patients. Gynecol. Oncol. 23:3 (1986), 316–322 PubMed PMID: 3957117.
20. Santin, A.D., Hermonat, P.L., Ravaggi, A., Bellone, S., Roman, J.J., Smith, C.V., Pecorelli, S., Radominska-Pandya, A., Cannon, M.J., Parham, G.P., Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol. Obstet. Investig. 51:4 (2001), 254–261 doi: 58060. PubMed PMID: 11408737.
21. Giuntoli, R.L. 2nd, Webb, T.J., Zoso, A., Rogers, O., Diaz-Montes, T.P., Bristow, R.E., Oelke, M., Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 29:8 (2009), 2875–2884 PubMed PMID: 19661290.
22. Tran, E., Nielsen, J.S., Wick, D.A., Ng, A.V., Johnson, L.D., Nesslinger, N.J., McMurtrie, E., Webb, J.R., Nelson, B.H., Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines. PLoS One, 5(12), 2010, e15625, 10.1371/journal.pone.0015625 PubMed PMID: 21203522; PMCID: PMC3008736.
23. Conlon, K.C., Lugli, E., Welles, H.C., Rosenberg, S.A., Fojo, A.T., Morris, J.C., Fleisher, T.A., Dubois, S.P., Perera, L.P., Stewart, D.M., Goldman, C.K., Bryant, B.R., Decker, J.M., Chen, J., Worthy, T.A., Figg, W.D. Sr., Peer, C.J., Sneller, M.C., Lane, H.C., Yovandich, J.L., Creekmore, S.P., Roederer, M., Waldmann, T.A., Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 33:1 (2015), 74–82, 10.1200/JCO.2014.57.3329 PubMed PMID: 25403209; PMCID: PMC4268254.
24. Patidar, M., Yadav, N., Dalai, S.K., Interleukin 15: a key cytokine for immunotherapy. Cytokine Growth Factor Rev. 31 (2016), 49–59, 10.1016/j.cytogfr.2016.06.001 PubMed PMID: 27325459.
25. Bachanova, V., Miller, J.S., NK cells in therapy of cancer. Crit. Rev. Oncog. 19:1–2 (2014), 133–141 PubMed PMID: 24941379; PMCID: PMC4066212.
26. Pilipow, K., Roberto, A., Roederer, M., Waldmann, T.A., Mavilio, D., Lugli, E., IL15 and T-cell stemness in T-cell-based cancer immunotherapy. Cancer Res. 75:24 (2015), 5187–5193, 10.1158/0008-5472 CAN-15-1498. PubMed PMID: 26627006; PMCID: PMC4681597.
27. Oh, S., Perera, L.P., Burke, D.S., Waldmann, T.A., Berzofsky, J.A., IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8 + T cells. Proc. Natl. Acad. Sci. U. S. A. 101:42 (2004), 15154–15159 Epub 2004/10/13. doi: 0406649101 [pii]10.1073/pnas.0406649101. PubMed PMID: 15477598; PMCID: 524066.
28. Kobayashi, H., Dubois, S., Sato, N., Sabzevari, H., Sakai, Y., Waldmann, T.A., Tagaya, Y., Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 105:2 (2005), 721–727, 10.1182/blood-2003-12-4187 Epub 2004/09/16 2003-12-4187 [pii]. PubMed PMID: 15367431.
29. Rautela, J., Huntington, N.D., IL-15 signaling in NK cell cancer immunotherapy. Curr. Opin. Immunol. 44 (2016), 1–6, 10.1016/j.coi.2016.10.004 PubMed PMID: 27835762.
30. Geller, M.A., Bui-Nguyen, T.M., Rogers, L.M., Ramakrishnan, S., Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer. Int. J. Gynecol. Cancer 20:6 (2010), 918–925, 10.1111/IGC.0b013e3181e5c442 PubMed PMID: 20683396.
31. Burleson, K.M., Boente, M.P., Pambuccian, S.E., Skubitz, A.P., Disaggregation and invasion of ovarian carcinoma ascites spheroids. J. Transl. Med., 4(6), 2006, 10.1186/1479-5876-4-6 PubMed PMID: 16433903; PMCID: PMC1397876.
32. Foley, B., Cooley, S., Verneris, M.R., Curtsinger, J., Luo, X., Waller, E.K., Weisdorf, D.J., Miller, J.S., NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood 118:10 (2011), 2784–2792, 10.1182/blood-2011-04-347070 Epub 2011/07/16. PubMed PMID: 21757615; PMCID: 3172795.
33. Gubbels, J.A., Felder, M., Horibata, S., Belisle, J.A., Kapur, A., Holden, H., Petrie, S., Migneault, M., Rancourt, C., Connor, J.P., Patankar, M.S., MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol. Cancer, 9(11), 2010, 10.1186/1476-4598-9-11 PubMed PMID: 20089172; PMCID: PMC2818693.
34. Krockenberger, M., Dombrowski, Y., Weidler, C., Ossadnik, M., Honig, A., Hausler, S., Voigt, H., Becker, J.C., Leng, L., Steinle, A., Weller, M., Bucala, R., Dietl, J., Wischhusen, J., Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J. Immunol. 180:11 (2008), 7338–7348 PubMed PMID: 18490733; PMCID: PMC3607742.
35. Felices, M., Lenvik, T.R., Davis, Z.B., Miller, J.S., Vallera, D.A., Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells. Methods Mol. Biol. 1441 (2016), 333–346, 10.1007/978-1-4939-3684-7_28 PubMed PMID: 27177679.
36. Davis, Z.B., Felices, M., Verneris, M.R., Miller, J.S., Natural killer cell adoptive transfer therapy: exploiting the first line of defense against cancer. Cancer J. 21:6 (2015), 486–491, 10.1097/PPO.0000000000000156 PubMed PMID: 26588681; PMCID: PMC4763946.
37. Dunn, G.P., Old, L.J., Schreiber, R.D., The three Es of cancer immunoediting. Annu. Rev. Immunol. 22 (2004), 329–360, 10.1146/annurev.immunol.22.012703.104803 Epub 2004/03/23. PubMed PMID: 15032581.
38. Dunn, G.P., Old, L.J., Schreiber, R.D., The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:2 (2004), 137–148, 10.1016/j.immuni.2004.07.017 Epub 2004/08/17. PubMed PMID: 15308095.
39. Rosenberg, S.A., IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192:12 (2014), 5451–5458, 10.4049/jimmunol.1490019 PubMed PMID: 24907378.
40. Nunez-Cruz, S., Scholler, N., Immunocompetent mouse model of ovarian cancer for in vivo imaging. Methods Mol. Biol. 1049 (2013), 425–433, 10.1007/978-1-62703-547-7_32 PubMed PMID: 23913235.
41. Mandai, M., Hamanishi, J., Abiko, K., Matsumura, N., Baba, T., Konishi, I., Dual faces of IFNgamma in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin. Cancer Res. 22:10 (2016), 2329–2334, 10.1158/1078-0432.CCR-16-0224 PubMed PMID: 27016309.
42. Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., Matsumura, N., Abiko, K., Baba, T., Yamaguchi, K., Ueda, A., Hosoe, Y., Morita, S., Yokode, M., Shimizu, A., Honjo, T., Konishi, I., Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 33:34 (2015), 4015–4022, 10.1200/JCO.2015.62.3397 PubMed PMID: 26351349.
43. Lin, A., Yan, W.H., Xu, H.H., Gan, M.F., Cai, J.F., Zhu, M., Zhou, M.Y., HLA-G expression in human ovarian carcinoma counteracts NK cell function. Ann. Oncol. 18:11 (2007), 1804–1809, 10.1093/annonc/mdm356 PubMed PMID: 17846022.
44. Rajagopalan, S., Long, E.O., A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 189:7 (1999), 1093–1100 PubMed PMID: 10190900; PMCID: PMC2193010.
45. Rajagopalan, S., HLA-G-mediated NK cell senescence promotes vascular remodeling: implications for reproduction. Cell. Mol. Immunol. 11:5 (2014), 460–466, 10.1038/cmi.2014.53 PubMed PMID: 24998350; PMCID: PMC4197210.